Ranbaxy Laboratories is currently trading at Rs. 362.90, down by 1.60 points or 0.44 % from its previous closing of Rs. 364.50 on the BSE.
The scrip opened at Rs. 364.30 and has touched a high and low of Rs. 370.95 and Rs. 362.00 respectively. So far 284505 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 490.15 on 06-Jan-2014 and a 52 week low of Rs. 253.95 on 02-Aug-2013.
Last one week high and low of the scrip stood at Rs. 375.00 and Rs. 353.25 respectively. The current market cap of the company is Rs. 15501.84 crore.
The promoters holding in the company stood at 63.41 % while Institutions and Non-Institutions held 19.55 % and 15.38 % respectively.
Ranbaxy Laboratories, India’s largest pharmaceutical company has recalled some batches of its generic version of cholesterol-lowering Lipitor drug in the United States after a dosage mix-up was detected. The company voluntarily recalled 64,626 bottles containing atorvastatin calcium tablets, the generic version of Pfizer Inc's cholesterol fighter Lipitor, after a pharmacist found a 20-milligram tablet in a sealed bottle marked for 10-milligram tablets.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1867.80 |
| Dr. Reddys Lab | 1301.30 |
| Cipla | 1433.10 |
| Zydus Lifesciences | 1112.10 |
| Lupin | 2356.55 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: